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Abstract
Background: Aldosterone is a mineralocorticoid hormone critically involved in arterial blood pressure regulation.
Although pharmacological aldosterone antagonism reduces mortality and morbidity among patients with severe
left-sided heart failure, the contribution of aldosterone to the pathobiology of pulmonary arterial hypertension
(PAH) and right ventricular (RV) heart failure is not fully understood.
Methods: The effects of Eplerenone (0.1% Inspra® mixed in chow) on pulmonary vascular and RV remodeling were
evaluated in mice with pulmonary hypertension (PH) caused by Sugen5416 injection with concomitant chronic
hypoxia (SuHx) and in a second animal model with established RV dysfunction independent from lung remodeling
through surgical pulmonary artery banding.
Results: Preventive Eplerenone administration attenuated the development of PH and pathological remodeling of
pulmonary arterioles. Therapeutic aldosterone antagonism – starting when RV dysfunction was established -
normalized mineralocorticoid receptor gene expression in the right ventricle without direct effects on either RV
structure (Cardiomyocyte hypertrophy, Fibrosis) or function (assessed by non-invasive echocardiography along with
intra-cardiac pressure volume measurements), but significantly lowered systemic blood pressure.
Conclusions: Our data indicate that aldosterone antagonism with Eplerenone attenuates pulmonary vascular rather
than RV remodeling in PAH.
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Background
Pulmonary arterial hypertension (PAH) is a devastating
disorder characterized by aberrant remodeling of pul-
monary arteries that results in sustained pulmonary
vasoconstriction, progressively increases pulmonary vas-
cular resistance (PVR) and right ventricular (RV) after-
load [1–3]. The persistent increase in afterload
maintains high shear stress on the RV myocardium and
leads to structural RV remodeling. Current interventions
approved for PAH therapy consist of vasodilators that
relieve the pulmonary vasoconstrictive component of the
disease while the underlying pathological lung and heart
remodeling progresses. Therefore, future treatment
strategies need to go beyond vasodilation by targeting
maladaptive remodeling processes in both, pulmonary
vasculature and RV myocardium.
An accumulating body of evidence suggests that dys-
regulation of the Renin-Angiotensin-Aldosterone-System
(RAAS) contributes to the pathogenesis of PAH [4–7].
In particular, the potential contribution of aldosterone –
a mineralocorticoid hormone critically involved in
* Correspondence: Ralph.Schermuly@innere.med.uni-giessen.de
1Universities of Giessen and Marburg Lung Center (UGMLC), Excellence
Cluster Cardio-Pulmonary System (ECCPS), Member of the German Center for
Lung Research (DZL), Aulweg 130, 35392, Giessen, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Boehm et al. BMC Pulmonary Medicine  (2018) 18:41 
https://doi.org/10.1186/s12890-018-0604-x
systemic blood pressure regulation – to PAH pathogen-
esis has recently drawn attention. Elevated levels of cir-
culating aldosterone were found in PH patients and
correlate with key cardio-pulmonary indices [8]. In line,
PH rat models demonstrate increased plasma and lung
tissue aldosterone concentrations that correlate with
cardio-pulmonary hemodynamics as well as pulmonary
vascular remodeling [8, 9] pointing towards a causative
role for aldosterone signaling in mediating adverse lung
remodeling as seen in PAH development. Pharmaco-
logical aldosterone antagonism by the FDA approved
drugs Spironolactone or Eplerenone, respectively, dir-
ectly reduced the pathologic pulmonary vascular remod-
eling in PAH animal models [10].
On a cellular level, it was demonstrated that aldoster-
one induces oxidative stress, endothelial dysfunction,
inflammation and fibrosis within the pulmonary vas-
culature. In pulmonary artery smooth muscle cells
(PASMCs), aldosterone promotes proliferation, viability
and apoptosis resistance [10, 11]. In pulmonary artery
endothelial cells (PAECs), aldosterone activates oxidant
stress signaling pathways that decrease the bioavailability
of the vasodilator nitric oxide, increases inflammation,
promotes fibrosis and increases cell proliferation and
migration [9, 12, 13]. In PAH, both PASMCs and PAECs
are considered key cell types, whose aberrant activation
is thought to drive maladaptive remodeling of the pul-
monary vasculature.
Aldosterone activation is also associated with de-
creased diuresis which elevates blood volume and
thereby blood pressure. Thus, by closely monitoring
electrolytes (sodium/fluid retention and potassium/mag-
nesium wasting), diuretics in combination with aldoster-
one antagonists effectively reduce blood volume, thereby
cardiac load and thus decrease RV wall stress in patients
with severe left heart failure [14]. Retrospectively, Spir-
onolactone and Eplerenone therapy have shown direct
beneficial effects on the RV in patients with PAH [15].
However, in an experimental rat model of RV failure in-
dependent from afterload, RAAS inhibition with Losar-
tan (angiotensin II receptor blocker) and Eplerenone had
no direct effects on either RV structure or function [16].
Eplerenone itself is a small molecule suggested to se-
lectively compete with aldosterone for mineralocorticoid
receptor binding and as compared with the nonselective
mineralocorticoid receptor antagonist Spironolactone
has lower affinity for progesterone and androgen recep-
tor binding which is associated with drug-induced
gynecomastia, breast pain and impotence [17]. Eplere-
none is clinically FDA approved for the treatment of
left-sided heart failure and systemic hypertension [18].
Taken together, clinical and experimental data suggest
that increased circulating aldosterone levels contribute
to the pathogenesis of PAH. To test this hypothesis, we
investigated whether pharmacological aldosterone an-
tagonism with Eplerenone attenuates pathological re-
modeling of the lung and the RV in experimental
mouse models. In order to differentiate afterload-
dependent from direct myocardial effects, we utilized
the SuHx and a pulmonary artery banding (PAB) mouse
model.
Methods
All experiments were performed according to the insti-
tutional guidelines that comply with national and inter-
national regulations (EU directive 2010/63). The local
authorities for animal research approved the study
protocol (Regierungspräsidium Giessen, Germany, Gi
32/2013 and The UK Home Office under PPL 40/3517).
Animal models
Adult male C57BL/6 J mice were purchased from
Charles River Laboratories (Sulzfeld, Germany and
United Kingdom) and housed under controlled condi-
tions with free access to rodent chow and tap water.
Mice were kept for three weeks under normobaric
hypoxia (~ 10% O2) and were concomitantly given an in-
jection of sugen5416 (20 mg/kg dissolved in MCC,
Tocris) once per week subcutaneously. All animals were
randomly assigned for either placebo (standard diet,
hereafter referred to as SuHx) or Eplerenone therapy
(hereafter referred to as Epl) starting on day one for add-
itional three weeks. Effective dosing was estimated ac-
cording to prior reports demonstrating efficacy of
200 mg/kg Eplerenone administration [19, 20], where-
fore 50 mg Inspra® tablets were homogenized and mixed
into standard rodent chow (Altromin, Lage, Germany)
to receive a final concentration of 0.1% Eplerenone
mixed in chow. Based on prior uptake data, this concen-
tration was estimated to result in ~ 200 mg/kg/d Eplere-
none. Control animals were kept under normobaric
conditions without sugen5416 injections and were fed
standard diet for the entire study period (hereafter re-
ferred to as cntrl). Maintained pressure overload was
surgically induced by pulmonary artery banding (PAB)
as described before [21–23]. PAB-challenged animals
were randomly assigned for either placebo (hereafter re-
ferred to as PAB) or Eplerenone (0.1% mixed in chow,
hereafter referred to as Epl) therapy starting one week
after disease commencement for additional two weeks.
Control animals underwent the identical surgical pro-
cedure without pulmonary artery clipping and were fed
control diet for the entire study period (hereafter re-
ferred to as sham).
Heart function assessment
All animals underwent non-invasive transthoracic im-
aging under continuous isoflurane anesthesia (1.5–2%)
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to measure RV cardiac output (CO), RV internal diam-
eter (RVID), tricuspid annular plane systolic excursion
(TAPSE) and myocardial performance index (MPI) in a
blinded manner as described before [24, 25]. Total pul-
monary resistance index (TPRi) was calculated as RV
systolic pressure divided by echocardiographically deter-
mined CI. Subsequently, intra-cardiac catheterization
was performed in all animals as previously reported
[21, 26]. Terminally, all mice were euthanized by ex-
sanguination and the RVs dissected for tissue weight
measurements.
Histomorphology
Formalin fixed tissue samples were dehydrated, paraffin
embedded, sectioned (5 μm) and stained for Alcian Blue
Elastic van Gieson (ABVEG), alpha smooth muscle actin
(αSMA) and von Willebrand factor (vWF) or picrosirius
red and wheat germ agglutinin (WGA) as described be-
fore [22, 26, 27].
Gene expression analysis
Total mRNA was extracted from frozen mouse RV tis-
sues, subsequently transcribed into cDNA and qPCR
was performed. Intron-spanning mouse-specific primers
for mineralocorticoid receptor (5’-CCGAGATCGTG
TATGCAGGC-3′ and 5’-CGCACGAACTGAAGGCT
GAT-3′), Collagen 1A1 (Col1A1; 5’-CCGGCTCCTGC
TCCTCTTAG-3′ and 5’-CCTCGGGTTTCCACGTC
TCA-3′), Collagen 3A1 (Col3A1; 5’-CCAGGAGCCA
GTGGCCATAA-3′ and 5’-GGGGCACCAGGAGAAC
CATT-3′) and porphobilinogen deaminase (PBGD; 5′-
GGGAA CCAGCTCTCTGAGGA-3′ and 5’-GAATTCC
TGCAGCTCATCCA-3′) were designed using sequence
information from the NCBI database and were pur-
chased from Metabion (Martinsried, Germany). Target
gene Ct values were normalized to the housekeeping
gene PBGD and expression was calculated as percentage
of sham controls.
Data analysis
All data are presented as mean ± SD analyzed with one-
way ANOVA followed by Newman-Keuls multiple com-
parison post-hoc test. Differences were considered statis-
tically significant for p < 0.05.
Results
Eplerenone attenuates SuHx-induced PH and pulmonary
vascular remodeling
Oral Eplerenone administration (0.1% mixed in chow)
for three consecutive weeks significantly attenuated the
development of PH in the SuHx mouse model (Sugen-
5416 injection followed by chronic hypoxia) demon-
strated by reduced RV hypertrophy (1.2 ± 0.1 vs. 1.4 ±
0.1, p < 0.05) (RV/BW, Fig. 1a) and reduced RV systolic
pressure (33.8 ± 4.3 vs. 39.5 ± 4.0 mmHg, p < 0.05)
(RVSP, Fig. 1b) as compared with controls. Total
pulmonary resistance index tended to decrease upon
Eplerenone administration (48.6 ± 13.0 vs. 51.4 ±
7.2 mmHg∙ml− 1∙min− 1∙g− 1, p > 0.05) (TPRi, Fig. 1c)
without affecting systemic blood pressure (82.8 ± 10.0 vs.
79.7 ± 8.8 mmHg, p > 0.05) (systemic BP, Fig. 1d) indicat-
ing a selective direct effect on the diseased pulmonary
circulation. Reduced remodeling of pulmonary arteries
was demonstrated by histomorphology (Fig. 1e) and
quantified as medial hypertrophy (0.47 ± 0.08 vs. 0.64 ±
0.05, p < 0.05) (media/cross sectional vessel area, Fig. 1f )
and percentage of muscularized pulmonary arterioles
(Fig. 1g).
Eplerenone therapy reduces systemic blood pressure
upon chronic RV pressure overload without direct effects
on RV structure or function
Therapeutic efficacy of Eplerenone – starting after one
week when animals in both PAB groups showed com-
parable signs of established RV dysfunction (data not
shown) – normalized mineralocorticoid receptor gene
expression in the RV (92 ± 12% vs. 118 ± 8%, p < 0.05)
(Fig. 2a) without affecting RV hypertrophy (1.3 ± 0.4 vs.
1.1 ± 0.2, p > 0.05) (RV/BW, Fig. 2b), RV systolic blood
pressure (54.0 ± 13.7 vs. 55.7 ± 8.7 mmHg, p > 0.05)
(RVSP, Fig. 2c) or cardiac output (9.8 ± 2.2 vs. 10.3 ±
1.8 ml∙min− 1, p > 0.05) (Fig. 2d) as compared with pla-
cebo controls, demonstrating no direct cardioprotective
effects of Eplerenone on the RV. Importantly, systemic
blood pressure dropped down (52.0 ± 11.3 vs. 69.8 ±
6.5 mmHg, p < 0.05) (Fig. 2e) indicating effective dosing
and a significant systemic impact of Eplerenone on the
stressed heart. Pressure-volume analysis (Fig. 2f ) demon-
strated unchanged contractility by RV end-systolic elas-
tance (1.04 ± 0.08 vs. 1.02 ± 0.11 mmHg∙μl− 1, p > 0.05)
(Ees, Fig. 2g). In addition, echocardiography revealed no
change in RV dilatation (unchanged RV internal diam-
eter (2.4 ± 0.1 vs. 2.1 ± 0.3 mm, p > 0.05) (RVID, Fig. 2h))
and tricuspid annular plane systolic excursion (1.0 ± 0.1
vs. 1.0 ± 0.1 mm, p > 0.05) (TAPSE, Fig. 2i) upon Eplere-
none therapy as compared with placebo controls.
Furthermore, chronic pressure overload-induced struc-
tural RV adaptation remained unaltered by Eplerenone
therapy as total RV collagen content (8.6 ± 1.4 vs. 8.5 ±
0.4%, p > 0.05) (Fig. 3a), Col1A1 (147 ± 7 vs. 159 ± 14%,
p > 0.05) (Fig. 3b) and Col3A1 (196 ± 25 vs. 227 ± 23%,
p > 0.05) (Fig. 3c) gene expression were not affected.
Also, pharmacological aldosterone antagonism had no
effect on cardiomyocyte hypertrophy (23.9 ± 0.6 vs. 20.9
± 0.8 μm, p > 0.05) (CM diameter, Fig. 3d) and heart fail-
ure marker gene expression (221 ± 6 vs. 220 ± 16%, p >
0.05 for ANP, Fig. 3e and 167 ± 10 vs. 154 ± 4%, p > 0.05
for BNP, Fig. 3f ).
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Discussion
The current study demonstrates that oral administration
of an aldosterone receptor antagonist attenuates mal-
adaptive remodeling of the pulmonary vasculature with-
out direct effects on RV structure and function in rodent
models. Eplerenone decreased SuHx-induced remodel-
ing of small pulmonary arteries without affecting the
systemic circulation. In a PAB mouse model, Eplerenone
induced systemic hypotension in animals with estab-
lished RV dysfunction - most likely due to cardiac
unloading - while RV structure and function remained
unaffected, demonstrating no direct cardioprotective ef-
fects independent from afterload. Taken together, these
data suggest that aldosterone plays a pathological role in
maladaptive remodeling of the pulmonary vasculature
rather than the RV. The therapeutic effect of Eplerenone
on the diseased pulmonary circulation, however, remains
to be characterized (including the effects of Eplerenone
on PASMCs and PAECs).
The development of PH in mice following vascular
endothelial growth factor receptor (VEGFR) blockade
and chronic hypoxia (SuHx model) was effectively atten-
uated by concomitant treatment with the oral available
aldosterone antagonist Eplerenone (Inspra®, 0.1% mixed
in standard chow) through reduced remodeling of small
pulmonary arteries. Eplerenone was oral available and
efficacious by decreasing RV systolic pressure and hyper-
trophy without affecting the systemic circulation - show-
ing a direct effect on the pulmonary circulation. We
estimated 0.1% Eplerenone mixed in chow to result in ~
a
d
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Fig. 1 Eplerenone attenuates SuHx-induced PH and pulmonary vascular remodeling. Preventive Eplerenone administration (Inspra®, 0.1% mixed in
chow) to mice attenuated the development of SuHx-induced RV hypertrophy (RV/BW, mg/g; a) and increased RV systolic pressure (RVSP, mmHg;
b). Total pulmonary resistance index (TPRi, ml− 1∙min− 1∙g− 1; c) and systemic blood pressure (systemic BP, mmHg; d) remained unaltered by Eplere-
none administration. Representative lung sections stained for Alcian Blue Elastic van Gieson (ABEVG), smooth muscle actin (SMA) and von Willeb-
rand factor (vWF) are shown in e. Medial hypertrophy is presented as ratio of media to cross sectional area [CSA] (f). Remodeling of pulmonary
blood vessels is demonstrated by muscularization (percentage of vessels). n = 5–10 mice per group; *: p < 0.05 vs. cntrl; †: p < 0.05 vs. SuHx
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200 mg/kg/d effective dosing, confirmed by PH attenu-
ation in the SuHx model, while an exact free plasma
concentration for Eplerenone is not available, may vary
between animals and is a clear limitation to this study.
Though, a pathological role for aldosterone in maladap-
tive remodeling of pulmonary arteries has previously
been described in PH rat models. In monocrotaline-
induced PH, pharmacological aldosterone antagonism
with either Spironolactone or Eplerenone decreased vas-
cular hyperplasia and vessel thickening [10, 11]. Also, al-
dosterone antagonism has been shown to reduce
neointimal hyperplasia in rats with SuHx-induced PH
[10]. These data are consistent with the decreased pul-
monary vascular remodeling observed in the current
study, which show that preventive Eplerenone adminis-
tration reduced vascular thickening. On a cellular level,
previous studies have demonstrated that aldosterone
activates an Akt/mTOR/Raptor axis that promotes
pulmonary artery smooth muscle cell (PASMC)
proliferation, cell migration, viability and apoptosis re-
sistance [10, 11]. It was shown that chronic hypoxia
itself selectively induces aldosterone synthesis autono-
mously in pulmonary artery endothelial cells (PAECs)
by upregulation of the steroidogenic acute regulator
protein (StAR). Elevated aldosterone levels were linked
to vasoconstriction by PAEC-derived endothelin 1 re-
lease, reactive oxidant signaling, reduced nitric oxide
bioavailability and fibrosis [9, 12, 13]. In PAH, both
PASMCs and PAECs are considered key cell types
whose aberrant activation leads to pulmonary vascular
remodeling that results in a sustainably increased RV
afterload.
Therapeutic strategies for the treatment of PAH aim
to halt or even reverse maladaptive lung remodeling
thereby reducing RV afterload, wall stress, myocardial
oxygen consumption, and ischemia to improve the con-
tractile state of the heart. Currently, RV afterload and
wall stress reduction in PAH is achieved through
a
d e f
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Fig. 2 Eplerenone reduces systemic blood pressure without direct effects on RV structure and function upon PAB. Eplerenone therapy normalizes
RV mineralocorticoid receptor gene expression (MR expression, percentage of sham; a without affecting RV hypertrophy (RV/BW, mg/g; b RV
systolic pressure (RVSP, mmHg; c or cardiac output (ml∙min− 1, d while systemic blood pressure (systemic BP, mmHg; e dropped down
significantly. Representative pressure-volume loops with lined end-systolic elastances (f). Quantification of end-systolic elastance (Ees, mmHg∙μl; g),
echocardiography-derived RV internal diameter (RVID, mm; h) and Tricuspid annular plane systolic excursion (TAPSE, mm; i) reveal no difference
between PAB and Eplerenone treated mice. n = 5–7 mice per group; *: p < 0.05 vs. cntrl; †: p < 0.05 vs. PAB
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pulmonary vasodilation [28]. Extensive work from the
field of left-sided heart failure has already revealed that
in addition to vasodilation, cardiac unloading through
blood volume reduction via RAAS inhibition beneficially
affects cardiac structure and function [14, 17]. In line,
several reports link dysfunctional RAAS activation to
PAH pathogenesis [4, 5, 7]. However, experimental and
clinical data demonstrate that RAAS blockade has no or
only minor direct beneficial effects on the RV myocar-
dium despite systemic unloading, suggesting that the re-
sponse to RAAS therapy might be critically different
between the LV and the RV [16, 29, 30]. The current
study extends these observations into oral administra-
tion of Eplerenone in mice with isolated RV pressure
overload independent from afterload in a dosage that
has proven efficacy in attenuating pathologic pulmonary
vascular remodeling. Beneficial effects observed in PH
animal models might be secondary due to afterload re-
ductions. Here, Eplerenone therapy starting when RV
dysfunction was established had no direct effect on the
RV myocardium while systemic blood pressure dropped
down. Interestingly, Eplerenone lowered the systemic
blood pressure only when administered to animals with
established RV dysfunction but not in the preventive
SuHx model, pointing towards a differential role in the
stressed RV which might be more vulnerable to aldoster-
one antagonism. Similar observations were made in a
study addressing the effects of RAAS inhibition on the
RV in a chronic pressure overload rat model [16].
A clinical role for Eplerenone has been described in
cardiovascular protection, was confirmed in several clin-
ical trials in patients with left-sided heart failure
(RALES, EPHESUS, ENPHASIS-HF) and has been ex-
tensively characterized in models of LV remodeling [14,
31, 32]. However, the molecular mechanisms are not
fully understood. A growing body of evidence suggests
that Eplerenone mediates its effects in part through
competing with aldosterone for mineralocorticoid recep-
tor binding – however, the mechanistic insights how
Eplerenone might affect mineralocorticoid receptor ex-
pression, as it was observed in this study, are still elusive.
In heart failure mouse models, genetic inactivation of
the mineralocorticoid receptor signaling pathway im-
proved LV function [33]. Specifically, cardiomyocyte but
not fibroblast restricted mineralocorticoid receptor defi-
ciency improved LV function and reduced LV dilation
upon trans-aortic constriction pointing towards a key
role for cardiomyocyte mineralocorticoid receptor sig-
naling in the pathogenesis of left heart failure [34]. In
line, Eplerenone therapy in wildtype animals with heart
failure improved LV function and reduced LV dilation
[35]. Whether elevated cardiac mineralocorticoid recep-
tor signaling is a disease consequence or drives heart
failure progression is not clear. In the current study, we
b
d
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Fig. 3 Eplerenone has no direct effect on pressure overload-induced
structural RV remodeling. Pharmacological aldosterone antagonism
with Eplerenone had no effect on RV total collagen content assessed
by picrosirius red stains (percentage of the total RV; a), Col1A1 (per-
centage of sham; b) and Col3A1 gene expression (percentage of
sham; c). Eplerenone did not affect cardiomyocyte hypertrophy (CM
diameter, μm; d), ANP (e) or BNP gene expression (percentage of
sham; f). n = 4–5 mice per group; *: p < 0.05 vs. cntrl
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report increased mineralocorticoid receptor gene expres-
sion directly in the hypertrophied RV – suggesting in-
creased mineralocorticoid receptor signaling - which
was normalized by Eplerenone therapy without func-
tional or structural RV improvements. These data show
that increased mineralocorticoid receptor activation is
rather a disease consequence than a driver of RV heart
failure pathogenesis.
Conclusions
In summary, this study reports a benefit of pharmaco-
logical aldosterone antagonism with Eplerenone in PAH
by directly targeting the pulmonary vasculature while
further studies are warranted to fully characterize the
therapeutic benefit of Eplerenone on the diseased pul-
monary vasculature and dissect the mechanistic role of al-
dosterone in PAH pathophysiology. The clinical relevance
of aldosterone antagonism as a therapeutic approach for
PAH is currently being evaluated in clinical trials. Patients
are recruited for a Phase 2, dose-ranging, randomized, pla-
cebo controlled study (→→→→ClinicalTrials.gov identi-
fier: NCT01712620) that is designed to compare the
effectiveness of Spironolactone in treating PAH versus
placebo. By targeting the maladaptive pulmonary vascu-
lar remodeling processes, that current PAH therapies
do not, aldosterone antagonism with Spironolactone is
expected to improve exercise capacity and endothelial
dysfunction in PAH. To find out whether an enhanced
cardiopulmonary fitness (exercise capacity and RV
function) improves the quality of life, Spironolactone in
combination with an endothelin receptor type A
blocker will be administered to PAH patients with a LV
ejection fraction > 50% in a prospective, double blind,
placebo-controlled phase 4 study (ClinicalTrials.gov
identifier: NCT02253394).
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